Safety results of the Canadian Expanded Access Program (EAP) of palbociclib (PAL) plus letrozole (L) in postmenopausal patients (pts) with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) deemed appropriate candidates for first-line (1L) endocrine therapy (ET) with L.

被引：1
|
作者：
Joy, Anil A.
Verma, Shailendra
Provencher, Louise
Theall, Kathy Puyana
Lu, Dongrui
Dequen, Florence
Rayson, Daniel
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e12534
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12534
引用
收藏
页数：6
相关论文
共 50 条
  • [31] Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) from the CompLEEment-1 trial
    Campone, M.
    De laurentiis, M.
    Zamagni, C.
    Kudryavcev, I.
    Agterof, M.
    Brown-Glaberman, U.
    Palacova, M.
    Chatterjee, S.
    Menon-Singh, L.
    Wu, J.
    Zhou, K.
    Martin, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [32] Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Analyses from PALOMA-3
    Cristofanilli, M.
    Slamon, D. J.
    Ro, J.
    Bondarenko, I.
    Im, S-A.
    Masuda, N.
    Colleoni, M.
    DeMichele, A.
    Loi, S.
    Verma, S.
    Iwata, H.
    Harbeck, N.
    Loibl, S.
    Andre, F.
    Theall, K. Puyana
    Huang, X.
    Giorgetti, C.
    Bartlett, C. Huang
    Turner, N. C.
    ANNALS OF ONCOLOGY, 2018, 29
  • [33] Overall survival (OS) with palbociclib (PAL) plus fulvestrant (FUL) in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Updated analyses from PALOMA-3.
    Cristofanilli, Massimo
    Rugo, Hope S.
    Im, Seock-Ah
    Slamon, Dennis J.
    Harbeck, Nadia
    Bondarenko, Igor
    Masuda, Norikazu
    Colleoni, Marco
    DeMichele, Angela
    Iwata, Sherene Loi Hiroji
    O'Leary, Ben
    Bananis, Eustratios
    Liu, Yuan
    Huang, Xin
    Kim, Sindy
    Lechuga, Mariajose
    Turner, Nicholas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib plus letrozole: Results from MONALEESA-2.
    Verma, Sunil
    O'Shaughnessy, Joyce
    Burris, Howard A.
    Campone, Mario
    Alba, Emilio
    Chandiwana, David
    Manson, Stephanie
    Sutradhar, Santosh C.
    Monaco, Mauricio
    Janni, Wolfgang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] ECONOMIC ANALYSIS OF COMBINATION THERAPY WITH ALPELISIB AND FULVESTRANT FOR TREATMENT OF HORMONE RECEPTOR-POSITIVE (HR plus ) AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER
    Delevry, D.
    Le, Q. A.
    VALUE IN HEALTH, 2020, 23 : S32 - S33
  • [36] Safety and efficacy of ribociclib (RIBO) plus letrozole (LET) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study
    De laurentiis, M.
    Mazza, M.
    Mansutti, M.
    Masetti, R.
    Ballatore, Z.
    Torrisi, R.
    Michelotti, A.
    Zambelli, A.
    Ferro, A.
    Generali, D.
    Vici, P.
    Coltelli, L.
    Fabi, A.
    Marchetti, P.
    Ballestrero, A.
    Spazzapan, S.
    Frassoldati, A.
    Sarobba, G.
    Grasso, D.
    Zamagni, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [37] EFFICACY plus SAFETY OF PALBOCICLIB (P) IN PATIENTS (PTS) ≤50 Y WITH HORMONE RECEPTOR- POSITIVE (HR plus )/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC): SUBGROUP ANALYSIS OF 2 RANDOMIZED PHASE 3 STUDIES
    Cristofanilli, Massimo
    Harbeck, Nadia
    Rugo, Hope
    Castrellon, Aurelio
    Joy, Anyl A.
    Verma, Sunil
    Im, Seock-Ah
    Iyer, Shrividya
    Puyana, Kathy
    Gauthier, Eric
    Huang, Xin
    Bartlett, Cynthia Huang
    Loibl, Sibylle
    Finn, Richard S.
    BREAST, 2018, 41 : S11 - S12
  • [38] Palbociclib (PAL) in male patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): Pt characteristics and treatment (Tx) patterns from the POLARIS study
    Blum, J. L.
    Dicristo, C.
    Gordon, D.
    Karuturi, M.
    Oubre, D.
    Jepsen, E.
    Cuevas, J.
    Lakhanpal, S.
    Zhang, Z.
    Drucker, M.
    Wang, Y.
    Tripathy, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S68 - S69
  • [39] Circulating tumor DNA (ctDNA) and serum thymidine kinase 1 activity (TKa) matched dynamics in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated in first-line (1L) with ribociclib (RIB) and letrozole (LET) in the BioItaLEE trial.
    Arpino, Grazia
    Bianchini, Giampaolo
    Malorni, Luca
    Zambelli, Alberto
    Puglisi, Fabio
    Del Mastro, Lucia
    Colleoni, Marco
    Montemurro, Filippo
    Bianchi, Giulia Valeria
    Paris, Ida
    Allegrini, Giacomo
    Tamberi, Stefano
    Cazzaniga, Marina Elena
    Orditura, Michele
    Zamagni, Claudio
    Grasso, Donatella
    Benelli, Matteo
    Callari, Maurizio
    Benfante, Antonina
    De laurentiis, Michelino
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] Ribociclib (RIBO) plus letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial
    Abdel-Razeq, H.
    Cottu, P. H.
    Ring, A.
    De laurentiis, M.
    Lu, J.
    Azim, H. A.
    Zamagni, C.
    Zhou, K.
    Wu, J.
    Menon, L.
    Martin, M.
    ANNALS OF ONCOLOGY, 2018, 29
12345